Izvi zvinogona here kuve chirevo chinotevera chechirwere cheshuga cheshuga?
IU.S. Food and Drug Administration (FDA) yakabvumira kushandiswa kweGPP-1 agonist itsva, Ozempic yeNovo Nordisk (semaglutide), sechirevo chekudya uye yekuvhidzira kwekurapa rudzi rwechipiri chirwere cheshuga kuvanhu vakuru. Zvinotarisirwa kuti zvivepo mukati memwedzi mitatu yokutanga ya 2018.
Izvi zvinokurudzira, zvikurukuru zvakapiwa kuti American Diabetes Association yakabudiswa munguva pfupi nezvezvinobatsira zvevamwe GLP-1 agonist muna 2018 Maitiro eShuga yeHIV.
Vakatarisa kukwanisa kwechirwere ichi kuderedza dambudziko rekukuvadza kwemwoyo yematambudziko, kusanganisira mwoyo yekurwisa, kurohwa, uye kushaya moyo yemwoyo, mune vanhu vakuru vane chirwere cheshuga chechipiri uye vakagadzika chirwere chemwoyo.
Ozempic Inoshanda Sei?
Semaglutide ndiyo yechinomwe GLP-1 agonist inogamuchirwa muUnited States uye yechina kamwe-yevhiki yega injectable kugamuchira kubvumirwa (Tanzeum ichakurumidza kugumiswa). Mishonga yemakliniki yakaratidza kuti ichava yakakosha.
Mune imwe nguva ichangobva kutaurwa "musoro-ku-musoro", Ozempic yakaratidza kukura kweA1c kudarika Trulicity (1.8 muzana kusvika 1.4 muzana) uye zvakanyanya kudarika Bydureon ( AstraZeneca), imwe kamwe kamwe kamwe nevhiki GLP-1 agonist. Semaglutide yakaratidzawo kuti inokonzera kurasikirwa kukuru kune vayo vasiri (anenge 10 kusvika kuzana 14 pounds kusvika pa5 kusvika pa7 pounds pavanoshandisa Victoza).
GLP-1 agonist, semaglutide, shanda kuderedza shuga yeropa nekutsvaga zvimwe zvikamu zvemuviri, kusanganisira uropi, musimba, pancreas, chiropa, uye mudumbu.
Zvichida chikamu chekushanda kwakagara mune semaglutide iyoyo ine 94 muzana yenhamba yevanhu GLP-1. Vanhu vazhinji vane chirwere chechirwere cheshuga vane mazamu maduku e GLP-1, izvo zvingaguma nehupamhi hwemashuga eropa.
Apo inorowa, GLP-1 agonist inotumira chiratidzo kuuropi kuderedza kudya kwemanyo nemvura; Mukuita kudaro, vanhu vane chirwere chechirwere cheshuga 2 vane mikana yekudya zvidimbu zvishoma, kurasikirwa uremu, uye kuderedza ropa ravo sutu.
Kunyange zvazvo uropi huri kuudzwa kuti ugare wakakwana, GLP-1 agonists inoshandawo mudumbu kuderedza asidi yekusvitsa uye kuderedza kudya kwegastric, iyo inoderedza kushanda kwekukurumidza kwekudya kunosiya mudumbu rako, kuwedzera kuzadza uye kuderedza kushandiswa kwemashuga ekutsvaga kweropa, kazhinji kazhinji chinokonzera kushungurudza.
Uyezve, GLP-1 agonists inobatsira kuderedza mushure mekudya kweropa sutu nekuita kuti pancreas iite insulin apo inosangana nekudya uye kuderedza hepatic (chiropa) glucose yakabuda (chirongwa chinonzi gluconeogenesis).
Migumisiro Yechiri
Kufanana nemishonga yose, kune ngozi yekuve nemigumisiro. Nyaya yakanyanya kufanana nayo inonzi yakanga iine unyoro kusvika kuenzanisa kushungurudza, izvo zvaiwanzoonekwa kuti zvishoma nezvishoma. Mamwe maitiro anowanzovhiringidza akaipa, anorondedzerwa mukati ma5 kubva muzana yevarwere vakabatwa neOzempic, vairutsira, chirwere, maronda emimba, uye kuvimbiswa.
Pane mhinduro dzemigumisiro iyi yaunogona kukurukura nachiremba wako kuti ave nechokwadi chokuti mushonga hausi kuparadza zuva nezuva. Yeuka, zvakagadzirirwa kukubatsira, kwete kukonzera zvimwe zvinetso.
Contraindications
Ozempic ine zvikomborero zvakawanda, asi hazvisi zvevanhu vose. Haifaniri kushandiswa nevanhu vane nhoroondo yemunhu kana yemhuri ye medullary thyroid carcinoma kana kune varwere vane multiple endocrine neoplasia syndrome rudzi rwechipiri.
Izvi ndezvokuti mumakonzo nemakonzo, semaglutide yakakonzera kuwedzera-kuwedzerwa kwechirwere uye kuwedzerwa-kwehutano-kuwedzerwa kwechiitiko chetachiona C-cell tumor (adenomas uye carcinomas). Saka, hazvizivikanwe kana Ozempic inokonzera utachiona hweC-cell tumors, kusanganisira medullary thyroid carcinoma (MTC), muvanhu.
Uyezve, vanhu vane nhoroondo yekushaya chirwere cheshuga retinopathy (chirwere cheziso) vanoodzwa kushandiswa kwemishonga iyi sezvo inogona kukuvadza zviratidzo uye zvinokonzera zvinetso. Yakaudzwa kuti njodzi yehutachiona hwekushaya chirwere cheshuga uye zvinetso zvinowedzera kune avo vanoshandisa Ozempic avo vakagadzira chirwere cheshuga chetinopathy kune avo vasingaiti.
Iko kunopfurikidza kunowedzera kunetseka kunogona kuenzaniswa nekuderedza kunonoka muA1c paunotanga mishonga. Many insulin inopa nyevero yakafanana.
Pakupedzisira, kuvanhu ivavo vane nhoroondo yepascreatitis, iyi mishonga haina kukurudzirwa. Zvidzidzo zvakaratidza kuti vanhu avo vanotora Ozempic vave vakarondedzera kupisa uye kusingaperi kwepancreatitis. Zvinotaurwa kuti vanhu vanosarudza kutora mishonga iyi vanocherechedza zvakanyatsonaka nokuda kwezviratidzo uye zviratidzo zvekuputika, kunosanganisira kurwadziwa kwakasimba kwepamuviri, dzimwe nguva kunopera kumberi kana kusina kurutsa. Kana pancreatitis ichifungidzirwa kuti mishonga inofanira kumira uye kana ichiongororwa, haifaniri kutangazve.
Kana iwe ukawira kune rimwe remapoka aya, usanzwa uora mwoyo nezvekuwana mushonga. Pane zvimwe zvingaitwa nachiremba wako anokurudzira iwe zviri nani.
Kutungamira uye Kusarudza
Ozempic inouya mune yakagadzirwa, yakagadzirirwa FlexTouch pen uye injovedwa pasi pemutana kusvika mumafuta masai kamwe kamwe pavhiki. Chirwere chekutanga chiri 0.25 mg yekutanga uye pashure pemavhiki mana chirechi ichiwedzerwa kusvika ku 0.5 mg kamwe kamwe. Kana mushure memasvondo mana kuwedzerwa ropa rekuisa glucose rinodiwa, chiremba wako anogona kuwedzera dhi 1 mg kamwe kamwe.
Iwe unogona kutora mishonga iyi chero nguva yezuva, kana usina kana kudya. Chiremba wako kana mudzidzisi ane chirwere cheshuga ane chiremba achakudzidzisa iwe nenzira yakakodzera yekujowa uye dosing.
Mari uye Utano Inishuwarenzi
Kazhinji yenguva, mishonga mitsva inowanzove yakanyanya kuwanda kana ichienzaniswa neye yave iripo kwenguva yakareba. Zvisinei, Novo Nordisk yakaratidza kuti Ozempic ichave yakatengeswa "par" pamwe chete nedzimwe kamwechete-vhiki nevhiki GLP-1 agonists. Zvinotarisirwa kuti avo vane inshuwarisi vanofanirwa kubhadhara mari yakafanana kune mamwe madhiragi mune iri kirasi.
Kazhinji, makadhi ekuchengetera mapepa anowanikwa kune avo vasina inshuwarisi. Kana uine mibvunzo chaiyo pamusoro pekubhadhara iwe unogona kutaura kumumiririri wekambani yaNovo Nordisk.
Future Developments
GLP-1 receptor agonist yakaratidza kuti inobatsira zvikuru kudyidzana kwekudya uye kuvhidzira kune avo vanhu vane chirwere cheshuga cheshuga. Uye nepo vachiri kusati varatidzwa senzira yokutanga yekurapa zvinodhaka, vari kushandiswa kakawanda sechipiri mutevedzeri. Nokuti vanowedzera mikana yekurasikirwa uye kuve nekugona kubatsira kune utano hwemwoyo, vangangodaro vari ivo vanoda kuwedzera- kugoverwa ku Metformin .
Zvinofadza kuti Novo Nordisk iri kushandawo kune zvimwe zviviri zvinogona kuitika zvechirwere ichi. Vari kuita zvidzidzo kuti vaone kana Ozempic ine zvigaro zvehutano hwemwoyo uyewo kushandiswa kweOzempic zvakananga sekurasikirwa-kurasikirwa kurapa kwekuwedzeredza.
Uyezve, mapepa epurogiramu yeOzempic inowanikwa mumakiriniki; izvi zvinogona kunge zviri yekutanga GLP-1 agonist kuti isasarudze chero injini zvachose. Izvozvo zvinogona kuva mutambo wose wevhidhiyo kune vanhu vane chirwere cheshuga-kuti vave nekukwanisa kubhadhara maitiro asina kufanana pasina jekisi kungave kunofadza zvikuru.
Shoko Rinobva
Kubva ikozvino, tsvakurudzo inoratidza kuti Ozempic inogona kupa hukuru hwehuga hwekutarisa uye kuora kurasikirwa.
Ichokwadi kuti kune zvimwe zvinetso-kujova mishonga, zvinowanzovhiringidza, kuwedzera kungozi yekutora pfungwa, uye zvingaita mari, kutumidza zvishomanana. Asi, iwe unofanirwa kuongorora zvinowedzera nehutano nehutano hwehutano hwako uye uone kana kuraswa kwemazivi, kuwedzerwa kwehuga kwehutano, pamwe nekugona kwehutano hwemwoyo kunopfuura zviitiko izvi.
Ramba uchitarisa kuti uwane mamwe mashoko pamusoro pemigumisiro yaro kune utano hwemwoyo pamwe nekuvandudzika kwezvinoitwa pakubika, zvakadai sekubvumirwa kwefomu yepiritsi.
> Sources:
> American Diabetes Association. Maitiro ekurapa muShuga-2018. Chirwere cheshuga 2018 Jan; 41 (Kuwedzera 1): S86-S104.
> Novo Nordisk. Ozempic-semaglutide injection .